Bodyport to Present First Real-World Heart Failure Monitoring Outcomes at THT 2026
SAN FRANCISCO, February 25, 2026 — Bodyport today announced that its abstract, “First Reported Real-World Outcomes of the Bodyport Cardiac Scale and Congestion Index in Heart Failure,” will be presented at the Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston on Wednesday, March 4.
Dr. Marat Fudim will present the research at 9:26 a.m. ET during First-in-Man / Early Feasibility Studies Abstracts Session III, part of the conference’s late-breaking clinical science program. The presentation will take place in Ensemble C–D, Level 2, at the Omni Boston Hotel at the Seaport.
The presentation will explore how Congestion Index–guided care is being integrated into remote heart failure management programs and its impact on clinical outcomes. Bodyport recognizes principal investigator Dr. Vishal Mehra for his leadership and Geisinger for its collaboration.
The FDA-cleared Bodyport Cardiac Scale supports simple daily at-home monitoring, combining weight and additional physiological measurements to help care teams follow changes in fluid status over time.
